Published in
American Society of Hematology, Blood, 6(125), p. 992-998, 2015
DOI: 10.1182/blood-2014-06-583369
Links
- ORCID
- American Society of Hematology | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Journal article published in 2014 by
Muhammad A. Mir,
Matthew J. Maurer 
,
Steven C. Ziesmer,
Susan L. Slager,
Thomas Habermann,
William R. Macon,
Brian K. Link ,
Sergei Syrbu,
Thomas Witzig,
Jonathan W. Friedberg,
Oliver Press,
Michael LeBlanc,
James R. Cerhan,
Anne Novak,
Stephen M. Ansell
,
Steven C. Ziesmer,
Susan L. Slager,
Thomas Habermann,
William R. Macon,
Brian K. Link ,
Sergei Syrbu,
Thomas Witzig,
Jonathan W. Friedberg,
Oliver Press,
Michael LeBlanc,
James R. Cerhan,
Anne Novak,
Stephen M. Ansell
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.